|
4th International AIDS Society Conference on HIV Pathogenesis and TreatmentSydney, Australia - July 22 - 25, 2007 |
A DECADE OF HIV SURVEILLANCE AMONG INJECTING DRUG USERS IN AUSTRALIA: RESULTS FROM THE AUSTRALIAN NEEDLE AND SYRINGE PROGRAM SURVEY
IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOAC202
Day C., Topp L., Iverson J., Maher L.
University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia
OBJECTIVES: HIV prevalence among injecting drug users (IDU) in Australia is approximately 2%. Widespread and early introduction of harm reduction initiatives including needle and syringe programs (NSP) have received widespread bipartisan political and community support. This study aimed to determine the prevalence and correlates of HIV infection among NSP attendees from 1995-2005.
METHODS: The Australian NSP Survey takes place annually one week in October at sentinel NSPs across the country. Participants complete a brief questionnaire covering demographics, injecting drug use and blood borne virus transmission risk behaviours; and provide a capillary blood sample. Aggregated data (1995-2005) were used to determine factors independently associated with HIV infection using multiple logistic regression.
RESULTS: Data were available for 24,457 NSP attendees over 11 year and across 48 sites. The majority of participants were male (65%), with a median age 30 years (13-87), been injecting drugs a median of 9 years (<1-71), and 77% were born in Australia. Seventy-eight percent reported their sexual preference as heterosexual, 10% as bisexual and 6% as homosexual. Serology was available for 22,983 (94%) participants, 273(1.2%) of whom tested HIV antibody positive. HIV prevalence varied across the study years from 2.1% in 1995 to 0.9% in 2005 (range 2.1%-0.8%). Compared to HIV negative participants, HIV positive participants were more likely to be older (AOR1.05; 95%CI 1.03-1.06), male (AOR: 4.37; 95%CI 2.96-6.46), identify as homosexual (AOR 32.11; 95%CI 23.69-43.54) or bisexual (AOR 4.44; 95%CI 2.76-7.15), but less likely to report daily injecting (AOR 0.74; 95%CI 0.56-0.98).
CONCLUSIONS: These data confirm that HIV prevalence among NSP attendees in Australia has been consistently low and suggest that the epidemiology of HIV in this group mirrors that evident in the broader Australian population, where the majority of exposures are attributed to male-to-male sexual contact. NSPs are a crucial component of Australia’s successful HIV surveillance mechanism.
Download PDF of this abstract.
2007-07-22
MOAC202
Global Responses to HIV Prevention Among Injection Drug Users
Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.